Skip to main content

Table 1 Overview of imaging examinations in naïve mice and treatment study

From: Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer

Mouse

Week 3

Week 4

Week 5

Total scans, week 3–5

Treatment study (end-point imaging, week 7/8) DWI + T2

Naïve, untreated tumors

M1

T2 + DWI + PET

    

M2

T2 + DWI + PET

T2 + PET

T2

 

Control (L)

M3

T2 + DWI + PET

 

T2 + PET

  

M4

T2 + DWI

    

M5

T2 + DWI

T2 + PET

   

M6

T2 + PET

T2 + PET

T2 + PET

  

M7

T2 + PET

T2 + PET

T2 + PET

  

M8

T2 + PET

T2 + PET

T2

  

M9

T2 + PET

T2 + PETa

T2

  

M10

T2 + PET

T2 + PETa

T2

 

Control

M11

T2 + PET

   

Treatment (L)

M12

T2 + PET

    

M13

T2 + PET

   

Treatment

M14

T2 + PET

    

M15

 

T2 + PET

   

M16

 

T2 + PET

   

M17

 

T2 + PET

  

Treatment

M18

  

T2 + PET

 

Control

M19

    

Control

M20

    

Treatment

M21

    

Treatment

T2—scans

14

10

8

32

9

DWI—scans

5

–

–

5

9

PETb—scans

12

10

4

26

0

  1. L indicates weekly longitudinal T2 + DWI imaging (in two mice) in the treatment study from week 4 until week 7/8 (control/treated mouse) DWI diffusion-weighted MRI, L longitudinal, T2 T2-weighted MRI
  2. aStatic PET only due to technical issues
  3. bPET refers to PET-CT imaging, however CT images were used as PET anatomical reference and attenuation correction only